Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAX201
- Development stage
- Phase 1
- Lead developer
- Guangzhou Sinanxin Biotech
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intranasal
01
Overview
SAX201 is a recombinant live-attenuated vaccine candidate developed for the prevention of respiratory syncytial virus (RSV) infection. It utilizes a human parainfluenza virus type 3 (hPIV3) vector to deliver and express the RSV fusion (F) protein. Designed for intranasal administration, SAX201 aims to induce both systemic and mucosal immunity, providing a dual layer of protection against RSV, which is a leading cause of lower respiratory tract infections in infants and the elderly. By using the hPIV3 backbone, the vaccine also potentially provides protection against parainfluenza virus type 3 infections, making it a bivalent candidate. The developer, Guangzhou Sinanxin Biotech, is advancing the drug through early-phase clinical trials in China.
02
Targets
HN (Hemagglutinin-neuraminidase protein)RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on SAX201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAX201.